Biotechnology - Licensing, Diabetes

Filter

Current filters:

LicensingDiabetes

Popular Filters

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Celladon signs option agreement with Servier

24-02-2014

USA-based biotech firm Celladon has entered into an option agreement with French independent drugmaker…

BiotechnologyCelladonDiabetesLicensingServier

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

Evolva to license EV-077 to Serodus

07-10-2013

Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

ThromboGenics gains rights to DME drug

06-09-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Sirona Biochem signs LoI with leading Chinese diabetes company

22-08-2013

Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Adocia re-acquires exclusive rights to insulin analog from US drug major

30-07-2013

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Mylan extends deal with Bioton to biosimilar insulins, as Actavis pulls out of JV

14-02-2013

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBiotechnologyBiotonDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca

07-01-2013

German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS),…

AstraZenecaBiotechnologyCell Culture Service GmbHDiabetesEvotecLicensingMedImmuneMergers & AcquisitionsPharmaceutical

Bristol-Myers Squibb signs option for Biocon's oral insulin drug candidate

19-11-2012

Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an option agreement with…

BioconBiotechnologyBristol-Myers SquibbDiabetesIN-105LicensingPharmaceuticalResearch

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance

10-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Janssen in-licenses insulin-producing beta cells from Evotec

10-07-2012

German biotech firm Evotec AG (EVT: TecDAX) has licensed to Janssen Pharmaceuticals, a unit of US health…

BiotechnologyDiabetesEvotecJanssenJohnson & JohnsonLicensing

Pfizer and Biocon cancel biosimilars deal

14-03-2012

Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Mochida diabetes deal with Merck; Vanda links with Megapharm

14-12-2011

Japanese mid-sized drugmaker Mochida Pharmaceutical (TYO: 4534) saw its shares jump 5.8% to 900 yen,…

BiotechnologyDiabetesFanaptLicensingMegapharmMerck & CoMochida PharmaceuticalNeurologicalPharmaceuticalVanda Pharmaceuticals

Amylin diabetes drug exenatide deal with Eli Lilly terminated, with $1.45 billion settlement to Lilly

09-11-2011

Shares of US biotech firm Amylin Pharmaceuticals fell 8.4% to $10.01 in pre-market trading yesterday,…

AmylinBiotechnologyBydureonByettaDiabetesEli LillyExenatide InjectionLicensingPharmaceutical

Back to top